ArticleAAS open research2019
African Pharmacogenomics Consortium: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa: Consolidating pharmacogenomics knowledge, capacity development and translation in Africa.
Article in AAS open research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer.Clinical and translational science · 2024Pooled it
- Bridging the pharmacogenomics gap: a survey of healthcare workers in South-Western Nigeria.The pharmacogenomics journal · 2026Article
- Strengthening Pharmacogenomics Implementation in Africa: Challenges and Opportunities - A Narrative Review.Health science reports · 2026Article
- Article
- Promoting training for African medical students and residents in designing and conducting neurological oncogenetic research: A viewpoint.Surgical neurology international · 2026Article
- A call to action for pharmacogenomics stewardship in South Africa.Frontiers in pharmacology · 2026Article
- Digital oncology frameworks in Africa: a scoping review of architectural patterns, digital maturity, and data equity implications.Frontiers in public health · 2026Article
- Characterization of the complex TB pharmacogenomic landscape in Africa using bioinformatic tools.Briefings in bioinformatics · 2025Article
- Article
- Science and Society: Pathways to Equitable Access and Delivery of Genomics Medicine in Africa.Current genetic medicine reports · 2025Review
- Pharmacogenomics of Chemotherapies for Childhood Cancers in Africa: A Scoping Review.Pharmacogenomics and personalized medicine · 2025Review
- Pharmacogenomics Tools for Precision Public Health and Lessons for Low- and Middle-Income Countries: A Scoping Review.Pharmacogenomics and personalized medicine · 2025Review
- Reply to "Inadequate representation of individuals of African ancestry in pharmacogenetics of tamoxifen research".Clinical and translational science · 2024Article
- CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children.Scientific reports · 2024Article
- 'Research ethics · 2024Article
- The Case for Pre-Emptive Pharmacogenetic Screening in South Africa.Journal of personalized medicine · 2024Article
- Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives.Frontiers in public health · 2024Review
- Article
- Ethnopsychopharmacology: Clinical and scientific writing pearls.The mental health clinician · 2023Article
- Research Participants' Preferences for Individual Results of Pharmacogenomics Research: A Case of a Ugandan HIV Research Institute.Journal of empirical research on human research ethics : JERHRE · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 6 countries.
Funding
Abstract
The African Pharmacogenomics Consortium (APC) was formally launched on the 6th September 2018. This white paper outlines its vision, and objectives towards addressing challenges of conducting and applying pharmacogenomics in Africa and identifies opportunities for advancement of individualized drugs use on the continent. Africa, especially south of the Sahara, is beset with a huge burden of infectious diseases with much co-morbidity whose multiplicity and intersection are major challenges in achieving the sustainable development goals (SDG), SDG3, on health and wellness. The profile of drugs commonly used in African populations lead to a different spectrum of adverse drug reactions (ADRs) when compared to other parts of the world. Coupled with the genetic diversity among Africans, the APC is established to promote pharmacogenomics research and its clinical implementation for safe and effective use of medicine in the continent. Variation in the way patients respond to treatment is mainly due to differences in activity of enzymes and transporters involved in pathways associated with each drug's disposition. Knowledge of pharmacogenomics, therefore, helps in identifying genetic variants in these proteins and their functional effects. Africa needs to consolidate its pharmacogenomics expertise and technological platforms to bring pharmacogenomics to use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.